<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39468945</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1598-6357</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>41</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of Korean medical science</Title><ISOAbbreviation>J Korean Med Sci</ISOAbbreviation></Journal><ArticleTitle>Long-Term Outcomes of COVID-19 and Risk Factors for Prolonged or Persistent COVID-19 in Lymphoma Patients: A Multicenter, Retrospective Cohort Study.</ArticleTitle><Pagination><StartPage>e263</StartPage><MedlinePgn>e263</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3346/jkms.2024.39.e263</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with hematologic malignancies exhibit persistent severe acute respiratory syndrome coronavirus 2 positivity over long periods after coronavirus disease 2019 (COVID-19) diagnosis. However, the frequency of, risk factors for, and prognosis of prolonged COVID-19 in immunocompromised patients remain unclear. Therefore, we investigated the long-term outcomes of COVID-19 in lymphoma patients and identified the associated factors and impact of prolonged COVID-19 on mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A multicenter retrospective cohort study of 583 lymphoma patients was conducted in 3 tertiary hospitals in South Korea. Patients receiving lymphoma treatment who were quarantined after obtaining a diagnosis of COVID-19 by polymerase chain reaction (PCR) or antigen test from August 2021 to September 2022 were examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 115 patients (19.7%) were diagnosed with COVID-19. Among 77 patients with clinical data, 24 had prolonged COVID-19. Patients in the prolonged COVID-19 group showed higher rates of receiving rituximab maintenance therapy following bendamustine and rituximab (BR) treatment for follicular lymphoma. This group did not show significant differences in clinical presentation within 30 days of COVID-19 diagnosis; however, it showed higher rates of re-admission due to COVID-19 pneumonia compared with the non-prolonged COVID-19 group. BR treatment followed by rituximab maintenance therapy is one of the risk factors for persistent PCR positivity, delayed or persistent pneumonia, and COVID-19 related admission after quarantine period. Prolonged COVID-19 was an independent risk factor for 1-year mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Prolonged COVID-19 was more frequent in lymphoma patients who received BR treatment followed by rituximab maintenance therapy and associated with unfavorable long-term outcomes and higher 1-year mortality.</AbstractText><CopyrightInformation>Â© 2024 The Korean Academy of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jung Ah</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-9891-5134</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Min</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0003-1763-5643</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Sangmin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0641-4493</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yongseop</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0116-6710</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeom</LastName><ForeName>Joon-Sup</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-8940-7170</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jun Yong</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-2775-3315</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Nam Su</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-9717-4327</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Su Jin</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-4025-4542</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jung Ho</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-5033-3482</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Seok</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-8986-8436</Identifier><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Haerim</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7926-9285</Identifier><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hyunsoo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2651-6403</Identifier><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Yu Ri</ForeName><Initials>YR</Initials><Identifier Source="ORCID">0000-0001-5505-0142</Identifier><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. GLASSY@yuhs.ac.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ahn</LastName><ForeName>Jin Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-3740-2826</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. COMEBACKTOSEA@yuhs.ac.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NRF-2021R1I1A1A01055124</GrantID><Acronym>NRF</Acronym><Agency>National Research Foundation of Korea</Agency><Country>Korea</Country></Grant><Grant><GrantID>6-2021-0066</GrantID><Acronym>YUCM</Acronym><Agency>Yonsei University College of Medicine</Agency><Country>Korea</Country></Grant><Grant><GrantID>2023-32-0045</GrantID><Acronym>YUCM</Acronym><Agency>Yonsei University College of Medicine</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Korean Med Sci</MedlineTA><NlmUniqueID>8703518</NlmUniqueID><ISSNLinking>1011-8934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>981Y8SX18M</RegistryNumber><NameOfSubstance UI="D000069461">Bendamustine Hydrochloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008223" MajorTopicYN="Y">Lymphoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="Y">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069461" MajorTopicYN="N">Bendamustine Hydrochloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bendamustine Hydrochloride</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Lymphoma</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Pneumonia</Keyword><Keyword MajorTopicYN="N">Rituximab</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39468945</ArticleId><ArticleId IdType="doi">10.3346/jkms.2024.39.e263</ArticleId><ArticleId IdType="pii">39.e263</ArticleId></ArticleIdList></PubmedData></PubmedArticle>